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Today mankind is experiencing an epidemic of 
opportunistic infections, among which mycoses take one 
of the leading places. Representatives of Candida genus 
are  the  most  often  causative  agents  of  mycoses. 
Candidiasis is an opportunistic mycosis, which proceeds 
with  lesions  of  the  mucous  membranes  and  the  skin; 
disseminated  forms,  more  often  with  the  pulmonary 
involvement  and  gastrointestinal  disorders,  can  be  in 
patients  with  severe  immunodeficiency  states  [1-5]. 
According to the international research the fungi of this 
genus  are  in  the  forth  place  in  importance  among 
infectious  agents  in  the  USA  [6-9].  Only  coagulase-
negative  and  coagulase-positive  staphylococci  and 
enterococci are ahead of them. A similar situation occurs 
in the countries of the former Soviet Union.  From the 
abovementioned  data  it  follows  that  trends  with 
candidemia are approximately similar in countries of the 
Eastern  and  Western  Hemisphere  by  the  epidemic 
characteristics (including the species ratio of pathogens). 
Unfortunately,  due  to  the  absence  of  opportunistic 
mycoses  recording  in  the  registration  cards  of  the 
Ministry of Health in the Russian Federation there are no 
statistic data on deep  mycoses, including candidemias. 
But, however, according to the sporadic data that include 
the  experience  of  clinicians  –  mycologists  of  the 
Research  Institute  of  Medical  Mycology  named  after 
P.N.  Kashkin  at  St-Petersburg  Medical  Academy  of 
Postgraduate Studies, who consult a number of medical 
institutions  having  the  patients  with  invasive  fungal 
infections, in particular fungemia, the number of cases of 
nosocomial  mycoses,  candidemias  approximately 
corresponds to the data published in the USA [2, 10-12]. 
This is largely due to the fact that there are similar risk 
factors in the world that are the cause of occurrence of 
candidiases and candidemias (as well as other mycoses 
and fungemias). 
The  genus  of  Candida  indudes  about  163 
species, but the main role in the pathological states of the 
human is played by the limited number of them; they are 
С. tropicalis, С. parapsilosi, С. glabrata, С. krusei, С. 
albicans with a significant predominance of the latter [2-
3, 8, 11]. Fungi of the genus Candida easily stained with 
methylene  blue,  and  Gram-Himozoyu  Romanovsky 
(picture 1). 
It should be noted that fungi of this genus are 
the  component  of  the  human  normal  intestinal  and 
mucous membranes microflora [2, 4-5, 11]. Disturbance 
of the body’s microbial cenosis caused by the inadequate 
use  of  drugs  of  a  wide  range  or  changes  in  the 
microenvironment  stimulates  the  excessive  growth  of 
Candida genus fungi [1-2, 9]. Metabolic and hormonal 
disorders (for example, diabetes mellitus, pregnancy, as 
well as intake of oral contraceptives) also contribute to 
development of candidiasis. 
 
 
Picture  1.  World  microscopy  fungus  C.  albicans 
(Gram staining). 
 
Immunodeficiency states and administration of 
immunodepressants  (for  example,  glucocorticoids)  can 
cause  different  forms  of  candidiasis  of  the  skin  and 
mucous  membranes  or  if  the  conditions,  in  which  a 
person works or lives, contribute to the development of 
candidal  infections  (high  humidity,  fever,  frequent 
contact with antibiotics or other chemical substances) [2-
3,  5,  12].  Candidiasis  is  characterized  by  intensive 
growth  of  these  fungi,  displacement  of  other 
representatives  of  the  human  normal  microflora.  In 
disseminated lesions it is formation of foci of necrosis 
and neutrophilic inflammatory infiltration [2, 4, 8, 11] 
(picture 2). 
 
 
 
Picture 2. Candidiasis 
 
The  absence  of  rapid,  sensitive  and  specific 
methods for diagnosis of invasive mycoses is a serious 
drawback in the treatment of such patients, and that is 
why a lot of persons die before receiving the adequate 
therapy [2, 8]. 
Diagnostic and therapeutic problems along with 
the successful use of antibacterial antibiotics in patients 21 
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with fever and neutropenia became the basis for carrying 
out the first two randomized studies of antifungal drugs 
in  the  80-ies  of  the  last  century.  It  means  empirical 
therapy of patients with fever and neutropenia when the 
antibacterial therapy is not effective; it is considered that 
the most obvious cause of such state of the patients is an 
undiagnosed  fungal  infection  –  usually  candidiasis  or 
aspergillosis [2, 4, 8, 11], and delay in treatment may end 
fatally.  Thus,  in  our  time  the  antifungal  therapy  is 
“blind”, i.e. without an accurate diagnosis of the fungal 
infection. The rational empirical antifungal therapy is the 
treatment  of  invasive  fungal  infection  at  a  very  early 
stage of the patient’s disease when there is a high risk of 
such infection [2, 4, 11]. 
Knowledge of a doctor and the state of a patient 
play  an  important  role  in  the  choice  of  the  common 
correct  approach  concerning  the  treatment  of  every 
patient suffering from candidemia or different forms of 
invasive disseminated candidiasis. However, the choice 
of antifungal drugs between Fluconazol, some azoles and 
polyene amphotericin В is small. Besides, there are a lot 
of  data  concerning  the  loss  of  Candida  genus  fungi 
sensitivity  to  traditional  antifungal  drugs  used  for 
decades [1, 2, 4, 7, 9].  
The  alternative  direction  to  fight  against 
candidal infection is to develop immunobiological drugs 
for treatment and prevention of candidiases. 
Various vaccines with the antigens of Candida 
genus fungi in their composition belong to these drugs 
[13-17]  
Development  of  technologies  for  obtaining 
antigens of Candida genus fungi began from the end of 
the  last  century.  Whole  cells  of  fungi  were  the  first 
antigens.  They  possess  the  most  complete  antigenic 
properties  [2,  18-20].  Researchers  used  filtrates  of  the 
culture fluid or filtrates of washings of fungal cells from 
a  dense  nutritional  medium  as  antigens.  The  obtained 
fungal cells were inactivated by various methods: some 
researchers  used  physical  methods  such  as  heating, 
ultrasonic  treatment,  etc.,  other  researchers  applied 
chemical  methods  such  as  formolation,  treatment  with 
alcohol, etc. 
Later on researchers found more appropriate to 
use extracts from the destroyed fungal cells for obtaining 
antigens.  Various  methods  –  mechanical,  physical, 
chemical and biological ones were used to disintegrate 
cells [2, 21-23]. Antigens consisted of fractions of the 
protein and glycoprotein nature. Each species of Candida 
had antigenic components of the glycoprotein nature that 
were  common  with  other  species  and  specific  for  the 
particular species. Lipid substances in the drugs obtained 
were  presented  in  minimal  quantities  and  probably  in 
combination with proteins [2, 24, 25, 26]. 
The  interest  to  mechanical  methods  of 
disintegration of Candida cells increased even more in 
connection  with  the  research  of  the  chemical 
composition and the  antigenic structure of the isolated 
cell walls of fungi [2, 21, 23, 27, 28]. Antigenic drugs 
were  prepared  by  the  physical  methods  of  cell 
destruction  –  autoclaving,  freezing  and  thawing  in 
different modes, electrolysis of cells in saline solution, 
ultrasound; by the chemical methods – by water-alcohol 
mixture,  diethylene  glycol,  glycerin;  surfactants 
(detergents) were also used [2, 21, 24, 26]. 
Isolation of antigens with the help of chemical 
extractants began in the 20-ies. Most researchers tried to 
obtain  antigens  by  several  methods  and  compare  their 
chemical  composition  and  activity.  Some  researchers 
preferred the cold water-alcohol extraction, others used 
the cell autoclaving with alcohol precipitation, and still 
others performed the extraction with trichloroacetic acid 
[2, 23, 25, 27]. The works of a number of researchers by 
the  end  of  the  50-ies  revealed  that  extracts  composed 
mainly  of  carbohydrate  components  –  polysaccharides 
had the greatest activity [2, 21, 22, 27]. The next period 
of  time  was  devoted  to  the  search  of  methods  for 
isolation of polysaccharides, their purification, the study 
of biochemical characteristics and activity. 
Before the 60 - 70-s the new data were obtained 
while  studying  the  structure  of  the  cells  of  Candida 
genus  fungi  and  the  chemical  composition  of  the  cell 
components.  It  was  found  that  the  main  part  of 
hydrocarbon components of cells were in the membrane 
[2,  21,  23,  27].  It  was  logical  to  assume  that 
polysaccharides  obtained  by  different  impact  on  the 
whole  cell  were  isolated  from  the  membrane.  Thus, 
researchers  began  to  study  carefully  the  isolated  cell 
walls. 
Some  researchers  fractionated  decontaminated 
cell walls treating them with 1 N solution of potassium 
hydroxide  [2,  22,  27].  Currently  such  methods  of 
disintegration  as  shaking  cells  with  glass  beads  in 
disintegrators,  crushing  the  cell  mass  by  a  pressure 
machine, destruction of cells by ultrasound, etc., are used 
to obtain isolated cell walls [2, 21, 25]. It has been found 
that in sequential extraction of antigenic substancesfrom 
Candida  genus  fungi  the  specificity  and  activity  of 
isolated  drugs  decrease  with  the  increase  of  the 
hydrolyzing agent rigidity [2, 23, 27]. 
Some researchers have gone beyond the study 
of  polysaccharides  of  the  cell  wall,  and  investigated 
extracellular  polysaccharides  of  Candida  genus  fungi, 
which  are  present  in  the  culture  fluid.  Extracellular 
polysaccharides are presented mainly by mannan, while 
in  the  cell  wall  there  are  glucan  and  mannan.  It  is 
connected  with  the  solubility  of  mannan.  Extracellular 
mannans  and  cell  wall  mannans  do  not  differ 
immunochemically,  structurally  a  cell  wall  mannan  is 
more  branched.  The  comparison  of  extracellular  and 
intracellular purified mannans and mannan-proteins has 
shown that a mannan-protein has a greater activity and 
specificity than a pure mannan considered earlier to be 
independently  responsible  for  the  activity  of  antigenic 
drugs [2, 21, 24, 27]. 
Extracellular  polysaccharides  –  mannan,  have 
less complex structure, low molecular weight and do not 
form the complex compounds with proteins and lipids. 
Polysaccharides of the cell wall of Candida genus fungi 
are high-molecular and complexing. Glucan is insoluble 
in  alkali,  provides  the  form  and  constancy  of  the  cell 
size, is partially soluble in water. Mannan has a branched 
structure, is soluble in water, easily isolated by various 22 
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methods of extraction of cell walls and the whole cells. 
Mannan is responsible for the antigen activity and cell 
specificity  of  yeast  fungi.  Their  structure  is  similar  in 
various species of Candida genus fungi and some other 
fungal genuses, and it provides cross reactions. Amino 
sugar – glucosamine, may play a role of a link in the 
membrane  between  proteins  and  polysaccharides. 
According  to  the  opinion  of  many  researchers, 
polysaccharides  are  in  the  cell  wall  as  the  mannan-
glucan-protein,  mannan-protein  and  glucan-protein 
complex.  The  attempt  of  the  maximum  purification  of 
the Candida genus fungi mannan, that is responsible for 
the  antigenic  activity,  from  other  biochemical 
components of the cell, in particular destruction of the 
complex  of  polysaccharides  with  protein,  does  not 
increase  the  activity  of  antigenic  drugs,  and  decrease 
their specificity [2, 21-22, 27]. 
Thus,  up  to  the  80  –  90-s  the  data  were 
obtained,  according  to  which  polysaccharides  with 
Candida genus fungi could be divided into 4 groups by 
their  localization  in  the  cell:  1)  noncellular 
polysaccharides released into the environment, 2) soluble 
or  “structural-metabolic”  polysaccharides  of  the  cell 
walls, 3) insoluble or “structural” polysaccharides of the 
membranes, 4) intracellular or “reserve” polysaccharides 
[2, 23, 26, 28].  
However,  all  further  studies  concerning 
development of vaccines for prevention and treatment of 
candidal infection in Ukraine stopped since the collapse 
of the Soviet Union. A difficult and uncertain economic 
and  political  situation  in  the  country  has  negatively 
impacted on all industries of Ukraine, and only now the 
work in this field partially begins. It should be noted that 
the research of the antigens of Candida genus fungi and 
development of vaccines against candidiasis have never 
stopped abroad, and in many countries on the territory of 
the former Soviet Union these studies are renewed and 
carried  out  actively  [15,  20,  22,  25].  It  is  worth 
mentioning  that  currently  no  domestic  vaccine  is 
produced  in  Ukraine  for  prevention  and  treatment  of 
candidal infection and no imported vaccines have been 
registered.  
At first to develop a vaccine against candidiasis 
it is necessary to analyze the data obtained by previous 
researchers and to check some of them. It is known that 
the use of the attenuated cells of Candida genus fungi, 
i.e.  live  vaccines,  is  impractical  in  connection  with 
impossibility of standardization and a possible activation 
of the causative agent. It is also not appropriate to use 
products  of  cell  metabolism  of  Candida  genus  fungi 
since the biochemical composition of metabolites differs 
from the composition of the substances contained in the 
composition  of  the  cells  of  Candida  genus  fungi,  and 
therefore,  they  do  not  provide  the  necessary  immune 
reactions. When developing a vaccine for prevention and 
treatment  of  candidal  infection  it  is  expedient  to  use 
inactivated cells of Candida genus fungi; to develop a 
dead vaccine. Some components of the cells of Candida 
genus fungi, namely proteins and carbohydrates, can be 
used for subunit vaccines. For the final choice of the type 
of  the  vaccine  required  it  is  necessary  to  develop  the 
technology  for  their  obtaining  and  to  study  immune 
responses. 
The technology of development of a dead and 
subunit vaccine for prevention and treatment of candidal 
infection supposes cultivation of  Candida genus fungi, 
and on their basis development of vaccines is planned. 
That  is  why  the  primary  task  is  to  substantiate  the 
technological  mode  for  cultivation  of  Candida  genus 
fungi.  
To develop a candidal vaccine it is necessary to 
determine  strains  or  species  of  microorganisms,  which 
are  the  most  widespread  or  main  causative  agents  of 
candidal  infection.  According  to  the  literature  data  in 
species identification of the fungi taken from the patients 
with candidal infection it has been found that practically 
in  all  cases  the  fungi  of  C.  albicans  species  are  the 
causative agents of the disease. The second widespread 
species is C. tropicalis occurring, as a rule, in association 
with  C.  albicans.  In  some  cases  C.  parapsilosis,  C. 
glabrata  and  C.  krusei  have  been  also  determined  in 
association  with  C.  albicans  or  C.  albicans  and  C. 
tropicalis) [2, 4, 20, 25]. Thus, conducting the research 
with  the  species  of  C.  albicans  and  C.  tropicalis  is 
promising  for  development  of  a  combined  vaccine  [2, 
30]. 
Therefore,  summarizing  the  above  said  the 
conclusion  can  be  made  that  the  research  concerning 
development of vaccine against candidiasis is the topical 
issue of modern pharmacy and medicine. 
 
References 
1. Borsch S. K. Combined use of antifungal agents and 
probiotics combustiology for treatment and prevention of 
candidiasis and irritable bowel syndrome / S. K. Borsch, 
T. R. Maslyak // Current gastroenterology. - 2011. - № 4. 
- P. 30-39. 
2. Yelinov N. P. Candida species and candidemia. State 
of the problem / N. P. Yelinov // Problems of medical 
mycology. – 2001. - V. 3, № 1. - P. 4-15. 
3. Kapustina O. A. Species composition and biological 
properties of fungi of the genus Candida isolated from 
various habitats of the human body / O. A. Kapustina, L. 
E.  Logacheva,  O.  L.  Kartashova  //  Proceedings  of  the 
Orenburg state agrarian university. - 2009. - V. 4, № 24. 
- S. 179-181. 
4.  Participation  candida  spp.  in  the  formation  of 
inflammatory  diseases  of  different  localization  /  A.  P. 
Godovalov,  G.  P.  Ozhgibesov,  L.  P.  Bykova, 
E. A. Nikulina // Problems of medical mycology. - 2008. 
- T. 10, № 2. - P. 34-36. 
55.Anaul  Kabir  M.  Candida  infections  and  their 
prevention / M. Anaul Kabir, Zulfiqar Ahmad // ISRN 
Preventive Medicine. – 2013. - P. 1-13. 
6. Odds F. C. CHROMagar Candida, a new differential 
isolation  medium  for  presumptive  identification  of 
clinically important Candida species / F. C. Odds, and R. 
Bernaerts // Clin. Microbiol. - 1994. - № 32. – P. 1923-
1929. 
7.Culture  and  Identification  of  Candida  albicans  from 
vaginal ulcer and separation of enolase on SDS-PAGE // 
P. Saravana Bhavan, R. Rajkumar, S. Radhakrishnan, C. 23 
Annals of Mechnikov Institute, N 2, 2014  
www.imiamn.org.ua /journal.htm 
 
 
Seenivasan, S. Kannan / Interer journal of biology. 2010. 
– V. 2, № 1. – P. 84–93.   
8. Identification of Candida albicans by using different 
culture  medias  and  its  association  in  potentially 
malignant and malignant lesions // Sonal Saigal, Ankur 
Bhargava, S. K. Mehra, Falguni Dakwala / Contemp Clin 
Dent. – 2011. - V. 2, № 3. – P. 188–193. 
9. Brown G. D. Innate antifungal immunity: the key role 
of phagocytes / G. D. Brown // Annu Rev Immunol. – 
2011. – Vol. 29. – P. 1–21. 
10.  LeibundGut-Landman,  S.  Immunity  to  fungi  /  S. 
LeibundGut-Landman,  M. Wutrich  & T. Hohl // Curr. 
Opin. Immunol. – 2012. – Vol. 24, № 2. – P. 449–458. 
Miceli E M. H. Emerging opportunistic yeast infections / 
M.  H.  Miceli, J. A. Díaz  and  S.  A.  Lee  //  The  Lancet 
Infectious Diseases. - 2011. - V. 11, № 2. - P. 142–151. 
11. The changing epidemiology of healthcare-associated 
candidemia  over  three  decades  /  D.  Diekema,  S. 
Arbefeville, L. Boyken, J. Kroeger & M. Pfaller // Diagn. 
Microbiol. Infect. Dis. – 2012. - № 73. – P. 45–48. 
12.  Zhukova  N.  V.  Modern  vaccines:  characterization 
and classification / N. V. Zhukova, I. M. Krivosheeva // 
Krimska journal is therapeutic. - 2013. - № 2. - P. 99-
104. 
13. Maluy V. P. Vaccines prevention:  general and the 
private questions, problems and prospects / V. P. Maluy 
//  Clinical  immunology.  Allergology.  Infectology.  - 
2009. - V. 23, № 4. - P. 5-22. 
14. Patent 2445109 The Russian Federation, МПК
7A 61 
K 36/062, A 61 K 47/02, C 12 N 1/14. Associated vaccine 
against  cutaneous  candidiasis  carnivores,  a  method  of 
manufacturing  associated  vaccine  against  cutaneous 
candidiasis carnivorous way of prevention and treatment 
of cutaneous candidiasis carnivores. A. M. Litvinov, N. A. 
Apanasenko. (RF). – 2010127796/10; stated 07.07.2010; 
published 07.07.2010. 
15.  Petrov  P.  V.  Immunogens  and  new  generation 
vaccine / P. V. Petrov, R. M. Khaitov - M.: GEOSTAR-
Medicine, 2011. – 608 p. 
 16.  Candida  albicans  vaccines  /  Aditi  Grover,  B.  S. 
Bhandari,  Nishant  Rai,  Pramesh  C  Lakhera  // 
Biotechnology International. – 2010. – Vol. 3, № 1. – P. 
4-17. 
17.  Immune  responses  induced  by  heat-killed 
Saccharomyces  cerevisiae:  a  vaccine  against  fungal 
infection / M. Liu et al. // Vaccine. – 2011. – V. 29. – P. 
1745–1753. 
18. Cassone A. Fungal vaccines: real progress from real 
challenges / A. Cassone // Lancet Infect dis. – 2008. – 
Vol. 8. – P. 114-124. 
19.  Cassone  A.  Development  of  vaccines  for  Candida 
albicans: fighting a skilled transformer / A. Cassone // 
Nature Reviews Microbiology. – 2013. – V. 11. P. 884–
891. 
20.  Han  Y.  Comparison  of  two  Candida  mannan 
vaccines: the role of complement in protection against 
disseminated candidiasis / Y. Han, K. Y. Rhew // Arch. 
Pharm. Res. – 2012. - № 35. – P. 2021–2027. 
21.  Synthetic  glycopeptide  vaccines  combining  β-
mannan and peptide epitopes induce protection against 
candidiasis  /  H.  Xin,  S.Dziadek,  D.  R.  Bundle,  J. 
E.Cutler //ProcNatlAcadSci U S A. – 2008. - № 105. –Р. 
13526-13531. 
22.Cutler J. E. Advances in combating fungal diseases: 
vaccines on the threshold / J. E. Cutler, G. S. Deepe, B. 
S. Klein // Nat Rev Microbiol. – 2007. – Vol. 5. – P. 13–
28. 
23.  David  A.  D'Argenio  A  decade  of  vaccines: 
integrating  immunology  and  vaccinology  for  rational 
vaccine  design  /  A.  D'Argenio  David,  B.  Wilson 
Christopher // Immunity. – 2010. – V. 33, № 4. –P. 437-
440. 
24.Host  defense  pathways  against  fungi:  the  basis  for 
vaccines  and  immunotherapy  /  Carvalho,  A.  et  al.  // 
Front. Microbiol. – 2012. – V. 3. – P. 1–9. 
25. Nabel G. J. Designing Tomorrow’s Vaccines / Nabel 
G. J. // N Eng J Med. – 2013. – V. 6, № 368. –Р. 551-60. 
26. Kashkina M. A. Influence of yeast polysaccharides 
on  immune  reactivity:  author.  diss.  ...  candidate.  biol. 
science / M. A. Kashkina - Leningrad, 1974. – 19 p. 
27.  Ruth  Ashbee  H.  The  yeast  handbook  /  H.  Ruth 
Ashbee, Elaine M. Bignell - Springer. - 2010. - 365 P.  
28. Janelle M. Hare Sabouraud agar for fungal growth / 
M.  Hare  Janelle  //  Laboratory  Protocols  in  fungal 
biolodgy. – 2013. - P. 211-216. 
29.  Combination  vaccines  //  A.  G.Skibinski  David,  C. 
Barbara Baudner, Singh Manmohan, T. O.’Hagan Derek 
/ Glob Infect Dis. – 2011. – V. 3, № 1. –P. 63–72. 
 
UDC 615.371:616-097:616.992.282 
BIOTECHNOLOGICAL DESCRIPTION OF 
TECHNOLOGIES FOR OBTAINING OF 
ANTIGENS OF CANDIDA GENUS FUNGI 
Rybalkin М.V. 
To develop the vaccine against candidal infection the 
various biotechnological methods for obtaining antigens 
of Candida genus fungi have been considered in the 
article. To obtain antigens for the prevention and 
treatment of candidiasis researchers use different types 
and parts of fungi of the genus Candida. Methods of 
preparation of antigens also vary widely including 
chemical, physical and physico-chemical techniques. Of 
all possible variants development and research of a dead 
and subunit vaccine based on C. albicans and C. 
tropicalis fungi that are the main causative agents of 
candidiasis have been chosen for further study.  
Key words: candidiasis; antigen, vaccine, immunity 
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ОСВІТЛЕННЯ ТЕХНОЛОГІЙ ОДЕРЖАННЯ 
АНТИГЕНІВ ГРИБІВ РОДУ CANDIDA 
Рибалкін М. В. 
У даній статті були розглянуті різні біотехнологічні 
методи одержання антегенів грибів роду Candida для 
розробки вакцини проти кандидозної інфекції. Для 
одержання антигенів для попередження та лікування 
кандидамікозу дослідники використовують різні 
види та частини грибів роду Candida. Методи 
одержання антигенів також широко варіюють 
включаючи хімічні, фізичні та фізико-хімічні 
прийоми. З усіх можливих варіантів для подальших 
досліджень було обрано розробка та дослідження 24 
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убитої та суб'єдиничної вакцини на основі грибів C. 
albicans та C. tropicalis, які є основними збудниками 
кандидамікозів.  
Ключові слова: кандидамікоз; антиген; вакцина; 
імунітет 
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ОСВЕЩЕНИЕ ТЕХНОЛОГИЙ ПОЛУЧЕНИЯ 
АНТИГЕНОВ ГРИБОВ РОДА CANDIDA 
Рыбалкин Н. В. 
В данной статье были рассмотрены различные 
биотехнологические методы получения антегенив 
грибов рода Candida для разработки вакцины против 
кандидозной инфекции. Для получения антигенов 
для предупреждения и лечения кандидамикоза 
исследователи используют различные виды и части 
грибов рода Candida. Методы получения антигенов 
также широко варьируют включая химические, 
физические и физико-химические приемы. Из всех 
возможных вариантов для дальнейших исследований 
были выбраны разработка и исследование убитой и 
субъединичной вакцины на основе грибов C. albicans 
и C. tropicalis , которые являются основными 
возбудителями кандидамикоз. Оба варианта вакцины 
предусматривают накопление биомассы грибов на 
основе которых и планируется разработка вакцин. 
Ключевые слова: кандидамикоз; антиген; вакцина; 
иммунитет 
 
 